V

Vicarious Surgical Inc
NYSE:RBOT

Watchlist Manager
Vicarious Surgical Inc
NYSE:RBOT
Watchlist
Price: 2.98 USD -0.67% Market Closed
Market Cap: 19.5m USD

Vicarious Surgical Inc
Investor Relations

Vicarious Surgical, Inc. engages in advancing the field of surgical robotics. The company is headquartered in Waltham, Massachusetts. The company went IPO on 2020-09-04. The firm is focused on developing a technology for the surgical procedures, improving patient outcomes and healthcare. The Company’s surgical technology combines human-like surgical robots and virtual reality to transport surgeons inside the patient for minimally invasive surgery (MIS). The company is a combination of advanced miniaturized robotics, computer science and three-dimensional (3D) visualization to build a single-incision surgical robot, called the Vicarious System. The vicarious system is designed to provide visualization with a stereoscopic camera that rotates in three degrees of freedom (yaw, pitch, and roll) to provide the surgeon with stereoscopic imaging of virtually every surface in the abdomen. The vicarious system contains approximately 28 sensors per instrument arm, which allows the system to provide real-time feedback to the surgeon on force, motion and other data that are intended to develop surgical procedures.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 12, 2025
AI Summary
Q3 2025

Cost Reduction: Vicarious Surgical cut operating expenses by 35% year-on-year and implemented headcount reductions to extend its cash runway.

Design Freeze Focus: The company's top priority remains achieving ‘design freeze’ for its surgical robot by end of 2026, despite some anticipated disruptions from outsourcing.

Outsourcing Initiative: Engaged PA Consulting to identify and manage outsourcing opportunities aimed at improving capital efficiency without derailing timeline.

Cash Burn: Q3 cash burn was about $10.5 million; management reiterated a full-year 2025 cash burn expectation of about $50 million, with plans to materially reduce burn in 2026.

Balance Sheet: Raised $5.9 million in gross proceeds from an October direct offering, boosting post-quarter liquidity.

Clinical Progress: Internal surgeon testing and OR labs showed significant improvements in system stability and procedural speed, notably reducing procedure times from 40 to 14 minutes in key tests.

Communication Efforts: Announced a new initiative to regularly update stakeholders via LinkedIn and the IR website, aiming for greater transparency.

Key Financials
Operating Expenses
$11.5 million
Research and Development Expenses
$8 million
General and Administrative Expenses
$3.2 million
Sales and Marketing Expenses
$350,000
Net Loss
$11.1 million
Net Loss Per Share
$1.86
Cash, Cash Equivalents and Short-term Investments
$13.4 million
Cash Burn (Q3)
$10.5 million
Cash Burn (Full Year 2025 Expected)
$50 million
Gross Proceeds from Direct Offering (October)
$5.9 million
Net Proceeds from Direct Offering (Post-Q3)
$5.2 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Adam David Sachs
Co-Founder, CEO & Director
No Bio Available
Mr. Sammy Khalifa
Co-founder, CTO & Director
No Bio Available
Mr. William J. Kelly CPA
CFO & Treasurer
No Bio Available
Mr. Randolph A. Clark
President
No Bio Available
Mr. Barry Stuart Greene F.A.C.S., M.D.
Co-founder & Chief Medical Officer
No Bio Available
Mr. John P. Mazzola
Chief Operating Officer
No Bio Available
Ms. Erin Checka
Head of Legal & Secretary
No Bio Available
Ms. Emma Plouffe
Vice President of Business Operations & People
No Bio Available

Contacts

Address
MASSACHUSETTS
Waltham
78 Fourth Avenue
Contacts